

Marta ZOLA, MD, FMH, FEBO

ISTRUZIONE E FORMAZIONE

Aprile 2022	Specialista in Oftalmologia (Diploma federale, FMH, Berna, Svizzera). Riconoscimento del titolo di medico specialista in oftalmologia da parte del Ministero della Salute Italiano.
Giugno 2021	Fellow dell' European board of Ophthalmology (FEBO)
Febbraio 2015	Abilitazione all'esercizio della professione, OMCEO, Torino. Iscritta all'albo dei medici chirurghi e Odontoiatri di Torino (Omceo), n. 26140
Sett 2008 –Lug 2014	Laurea in Medicina e Chirurgia, Università degli Studi di Torino Voto: 110/110 Dignità di Stampa
Giugno 2008	European Baccalaureate, Lycée Français Jean Giono di Torino.
Lingue straniere	Inglese C2 Francese C2 Spagnolo B2

PREMI E RICONOSCIMENTI ACCADEMICI

March 2022	Grant di ricerca dell'associazione AGORA, associazione francese di imaging retinico legata alla Società Francese di Retina (SFR), Francia.
May 2021	ARVO Travel Grant, Swiss Chapter affiliation, presentazione del poster. <i>"Galectin 3 and Central Serous Chorioretinopathy: a promising new biomarker"</i> Zola M, Gobeaux Camille, Javorsky Thara, Meester-Smoor Magda, Yzer Suzanne, Behar-Cohen Francine.
July 2020	Foundation Assessment in Visual Sciences, International Council of Ophthalmology (ICO), Grade A
March 2016	Bursary Place per la conferenza "The Lang Lecture" del Professor Alan Bird. London.
July 2014	Dignità di stampa per la tesi di laurea. Università di Torino. <i>"Dexamethasone intravitreal implant for non-infectious posterior uveitis"</i>

ESPERIENZA PROFESSIONALE

Nov 2021- oggi	Dottorato di Ricerca (PhD) "Il ruolo dei corticosteroidi nella Corioretinopatia Sierosa Centrale" presso la scuola dottorale ED563 MTCI (Médicaments, Toxicologie, Chimie, Imagerie); Université Paris Cité, Parigi. Supervisor: Prof. Francine Behar-Cohen
----------------	--

- Nov 2017- Ott 2021 Specializzazione in Oftalmologia con conseguimento del titolo federale di **medico specialista in Oftalmologia**. (FMH - Dipartimento federale dell'interno, Aprile 2022, Berna, Svizzera)
- **2017-2019: Ospedale Jules Gonin, Losanna, Svizzera (Fondation Asile des Aveugles, Hôpital Ophtalmique Jules Gonin).**
 - **2019-2021: Ophthalmopole ospedale Cochin di Parigi, Francia (APHP - Assistance Publique Hôpitaux de Paris).**
- Sett 2017- Ott 2017 Fellow clinico a "Rétinéllysée", studio privato specializzato in patologia retinica medica e chirurgica e imaging. (Dr. Ambresin, Dr. Pournaras, Dr. Vaudaux)
- Luglio 2017 Observership Clinica presso il reparto di Oftalmologia Ospedale Sao Juliao, Campogrande, Brasil
- **Esperienza clinica ambulatoriale.**
- Giu 2016 – Mag 2017 Ricerca in retina medica presso Hôpital Ophtalmique Jules-Gonin, Lausanne, Svizzera
- **Study recruiter, investigator, study coordinator**
- Ago 2015 – Mag 2016 Fellow di ricerca in retina medica presso Moorfields Eye Hospital, London.
- **Study recruiter and investigator**

RICERCA

Clinical Investigator

- Studio interventistico prospettico, caso-controllo « **Identification de biomarqueurs d'activation de la voie minéralocorticoïde dans le sérum et les milieux oculaires de patients présentant des néovaisseaux choroïdiens** » P.I : Prof. Behar-Cohen
- Studio prospettico randomizzato di fase III "**Allergan Abicipar Pegol 150998-005 (CEDAR) Study: The Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration**" P.I: Dr. Ambresin
- Studio prospettico randomizzato di fase III "**A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista™ (Anti PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular age-related macular degeneration.**" P.I: Dr. I. Mantel
- Studio prospettico randomizzato di fase III "**A Two-Year, Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration**" P.I: Dr. I. Mantel
- Studio di fase I: Utilizzo dell'Acido Ursodesossicolico (UDCA) nel distacco retinico regmatogeno. P.I: Prof. F.Behar-Cohen.
- Studio prospettico osservazionale multicentrico "**EDNA: Early Detection of Neovascular Age-related macular degeneration (AMD)**" Prof. U. Chakravarthy; Prof. S. Sivaprasad; Mr. P. Hykin.
- Studio prospettico multicentrico "**Vision Preference Value Scale and Patient Preferences in Choosing Therapies for Symptomatic Vitreomacular Interface Abnormalities**" Dr. N. Bressler (MD), Prof. S. Sivaprasad, Mr. D. Charteris, Mr. P. Hykin

PUBBLICAZIONI

Bibliometria, dati

- secondo Web Of Science, accesso 24/10/2023
H-index: 10
- secondo Scopus, accesso 24/10/2023
H-index: 11
- secondo Google Scholar, accesso 24/10/2023
H-index: 12

Capitoli di manuali

“ Les anti-inflammatoires non stéroïdiens“. **M. Zola**, F. Chast, F. Behar-Cohen. Rapport SFO 2023 Pharmacologie et biothérapies. Ed Elsevier.

“Central Serous Chorioretinopathy” **M. Zola**, S. Sivaprasad. CHOROIDAL DISORDERS, Ed. Elsevier, Jan 2017 (139-159).

Articoli scientifici

Ocular steroidome in human eyes and in eyes with complex central serous chorioretinopathy (CSCR). **Zola M**, Bousquet E, Bourges JL, Azan F, Zhao M, Jaworski T, Pussard E, Behar-Cohen F Sci Rep. 2023 Aug 29;13(1):14111. PMID: 37644063

The choroidal nervous system: a link between mineralocorticoid receptor and pachychoroid. Leclercq B, Weiner A, **Zola M**, Mejlacowicz D, Lassiaz P, Jonet L, Gélizé E, Perrot J, Viengchareun S, Zhao M, Behar-Cohen F. Acta Neuropathol. 2023 Nov;146(5):747-766 PMID: 37682293

Retinal stroke: research models, targets and experimental drugs. Daruich A, Robert MP, **Zola M**, Matet A, Bremond-Gignac D. Expert Opin Investig Drugs. 2023 Jul-Dec;32(8):755-760. PMID: 37651742

INDOCYANINE GREEN ANGIOGRAPHY OF TYPE 1 MACULAR NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION AND CENTRAL SEROUS CHORIORETINOPATHY REVEALS DIFFERENT DISEASE MECHANISMS. **Zola M**, Bousquet E, Favard C, Gigon A, Mantel I, Behar-Cohen F. Retina. 2023 Aug 1;43(8):1255-1263. PMID: 37155967

High Levels of C-Reactive Protein with Low Levels of Pentraxin 3 as Biomarkers for Central Serous Chorioretinopathy. Bousquet E, Chenevier-Gobeaux C, Jaworski T, Torres-Villaros H, **Zola M**, Mantel I, Kowalczyk L, Matet A, Daruich A, Zhao M, Yzer S, Behar-Cohen F. Ophthalmol Sci. 2023 Feb 3;3(3):100278. PMID: 36950301

Chronic Systemic Dexamethasone Regulates the Mineralocorticoid/Glucocorticoid Pathways Balance in Rat Ocular Tissues. **Zola M**, Mejlachowicz D, Gregorio R, Naud MC, Jaisser F, Zhao M, Behar-Cohen F. Int J Mol Sci. 2022 Jan 24;23(3):1278. PMID: 35163201

EVIDENCE AGAINST A CONTRALATERAL COATS PHENOTYPE BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. Daruich A, **Zola M**, Elalouf M, Munier FL. Retina. 2022 Jun 1;42(6):1184-1188. PMID : 35213527

“Mid-Phase Hyperfluorescent Plaques Seen on Indocyanine Green Angiography in Patients with Central Serous Chorioretinopathy” Elodie Bousquet, Julien Provost, **Marta Zola**, Richard F. Spaide, Chadi Mehanna, Francine Behar-Cohen. *J. Clin. Med.* 2021, 10, 4525. PMID: 34640543

“Oral Ursodeoxycholic Acid Crosses the Blood Retinal Barrier in Patients with Retinal Detachment and Protects Against Retinal Degeneration in an Ex Vivo Model.” Daruich A, Jaworski T, Henry H, **Zola M**, Youale J, Parenti L, Naud MC, Delaunay K, Bertrand M, Berdugo M, Kowalczyk L, Boatright J, Picard E, Behar-Cohen F. *Neurotherapeutics*. 2021 Feb 3. PMID: 33537951

“Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy”. Matet A, Jaworski T, Bousquet E, Canonica J, Gobeaux C, Daruich A, Zhao M, **Zola M**, Meester-Smoor M, Mohabati D, Jaisser F, Yzer S, Behar-Cohen F. *Sci Rep*. 2020 Nov 19;10(1):20175. PMID: 33214636

“Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment.” **Zola M**, D'Alessandro E, Sherif M, Nguyen A, De Azevedo D, Haeller C, Forestier E, Mantel I. *Graefes Arch Clin Exp Ophthalmol*. 2020 Nov 27. PMID: 33245426.

“Visual outcome and poor prognostic factors in acute retinal necrosis syndrome.” Mora P, **Zola M**, Favilla S, Tagliavini V, Calzetti G, Carta A, Gandolfi S, Guex-Crosier Y. *Graefes Arch Clin Exp Ophthalmol* 259, 277 (2021). PMID: 32840674

“Resolution of Corneal Fibrosis After Descemet's Stripping Automated Endothelial Keratoplasty: A Case Report.” **Zola M**, Kim J, Petrelli M, Schmutz L, Hashemi K, Kymionis G. *Ophthalmol Ther*. 2020 Jun;9(2):349-354. PMID: 32144575

“Pseudodonesis and image vibration after phacoemulsification: a new non refractive subjective visual complication in post cataract patients” **Zola M**, Tabibian D, Kymionis G. (accepted on *KliMo-SOG* Edition)

“Two-year follow up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy” **Zola M**, Daruich A, Matet A, Mantel I, Behar-Cohen F. *Br J Ophthalmol* 2018;Oct24 PMID: 30355720

“Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen.” Mantel I, **Zola M**, De Massougnes S, Dirani A, Bergin C. *Br J Ophthalmol* 2018;Aug30 [Epub ahead of print] PMID: 30166328

“OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IMAGING OF A CONGENITAL SIMPLE HAMARTOMA OF THE RETINAL PIGMENT EPITHELIUM.” **Zola M**, Ambresin A, Zografos L. *Retin Cases Brief Rep*. 2018 Aug 1. PMID: 30074568

“Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degeneration.” Mantel I, **Zola M**, Mir O, Gaillard R, Behar-Cohen F. *Br J Ophthalmol*. 2018 Jul 20. [Epub ahead of print] PMID: 30030393

“Evolution of fundus autofluorescence patterns over time in patients with chronic central serous chorioretinopathy.” **Zola M**, Chatziralli I, Menon D, Schwartz R, Hykin P, Sivaprasad S. *Acta Ophthalmol*. 2018 Apr 15. [Epub ahead of print] PMID: 29656602

“MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: RISK FACTOR EVALUATION FOR INDIVIDUALIZED TREATMENT NEED OF RANIBIZUMAB OR AFLIBERCEPT ACCORDING TO AN OBSERVE-AND-PLAN REGIMEN.” Mantel I, Dirani A, **Zola M**, Parvin P, De Massougnes S, Bergin C. *Retina*. 2018 Jan 23. [Epub ahead of print] PMID: 29370035

"Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone." **Zola M**, Briamonte C, Lorenzi U, Machetta F, Grignolo FM, Fea AM. Clin Ophthalmol. 2017 Nov 6;11:1949-1956. eCollection 2017. PMID: 29184384

"Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept." Parvin P, **Zola M**, Dirani A, Ambresin A, Mantel I. Graefes Arch Clin Exp Ophthalmol. 2017 Nov;255(11):2127-2134. PMID: 28798980

"Retinal Oximetry Differences Between Optic Disc Collateral Vessels and New Vessels." Nicholson L, Sivapathasuntharam C, **Zola M**, Hykin P, Bainbridge JW, Sivaprasad S. JAMA Ophthalmol. 2017 Sep 1;135(9):1003-1004. PMID: 28772311

"Identification of time point to best define 'sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data." Chatziralli I, Santarelli M, Patrao N, Nicholson L, **Zola M**, Rajendram R, Hykin P, Sivaprasad S. Eye (Lond). 2017 Nov;31(11):1594-1599. Epub 2017 Jun 16. PMID: 28622321

"RISK FACTORS FOR RECURRENCES OF CENTRAL SEROUS CHORIORETINOPATHY." Matet A, Daruich A, **Zola M**, Behar-Cohen F. Retina. 2018 Jul;38(7):1403-1414. PMID: 28570485

"Micro-Bypass Implantation for Primary Open-Angle Glaucoma Combined with Phacoemulsification: 4-Year Follow-Up." Fea AM, Consolandi G, **Zola M**, Pignata G, Cannizzo P, Lavia C, Rolle T, Grignolo FM. J. Ophthalmol. 2015; 2015:795357. PMID: 26587282

"Recent developments in the management of dry age-related macular degeneration" E. Buschini, A. M. Fea, C. Lavia, M. Nassisi, G. Pignata, **M. Zola**, F. M. Grignolo. Clinical Ophthalmology. Clin Ophthalmol. 2015 Apr 1; 9:563-74. PMID: 25878491

PRESENTAZIONI

Primo Autore

"Systemic spironolactone administration counterbalances the MR-induced effects of chronic dexamethasone in the RPE-Choroid complex of rodents" **Oral Presentation**, 23rd-27th April 2023, New Orleans, USA.

"Néovaisseaux maculaires et grossesse." **Oral presentation**, 2nd SOFEM Meeting (French Society of Women in Ophthalmology), 3rd June 2023, Paris. And 27th Ed. Retina News, Nice, France.

"Galectin 3 and Central Serous Chorioretinopathy: a promising new biomarker" Zola M, Gobeaux Camille, Javorsky Thara, Meester-Smoor Magda, Yzer Suzanne, Behar-Cohen Francine. **Poster Presentation**, ARVO Annual Meeting, Virtual Meeting, 1st-7th May 2021

"Central Retinal Thickness Measurements in Exudative Age-Related Macular Degeneration Refractory to Anti-VEGF: Influence of Time Parameters." **Zola M**, D'Alessandro E, Nguyen A, De Azevedo D, Haeller C, Forestier E, Mantel I. **Oral Presentation**, 19th Euretina Congress, 5th-8th September 2019, Paris

"Bilateral vascular anomalies in Coats disease suggest concurrent retinal vascular disease." **Zola M**, Ambresin A, Munier F. **Poster Presentation** 19th Euretina Congress, 5th-8th September 2019, Paris.

"Pseudodonesis and image vibration: an important post-operative issue after phacoemulsification" Zola M, Kheir V, Tabibian D, Kymionis G. Oral Presentation, Annual meeting of the Swiss Society of Ophthalmology, 30th-31st August 2018, Fribourg.

"Natural history of PAMM" **Zola M**, Ambresin A, Borruat FX, Mantel I. **Poster Presentation**, Annual meeting of the Swiss Society of Ophthalmology, 30th-31st August 2018, Fribourg.

"Longterm follow-up of choroidal neovascularisation in Best Disease on OCTA" Zola M, Ambresin A. **Image Gallery**, 5th International Congress on OCT Angiography and Advances in Angio-OCT, Rome 15th-16th December 2017

"Baissede vision rapide et indolore" Zola M, Munier F, Ambresin A. **Oral Presentation**, Retina Day Meeting, 9th November 2017, Lausanne

"Ocular and systemic risk factors for higher retreatment need with intravitreal anti-VEGF for neovascular age-related macular degeneration." Zola M, De Azevedo J, Marchionno L, Bergin C, Behar-Cohen F, Mantel I. **Poster Presentation**, 17th Euretina Congress, 7th-10th September 2017, Barcelona.

"Chronic central serous chorioretinopathy treated with mineralocorticoid-receptor antagonists: long-term follow up." Zola M, Daruich A, Matet A, Behar-Cohen F. **Poster Presentation**, ARVO Meeting, 6th-11th May 2017 Baltimore.

"OCT-A pattern of Isolated Hamartoma of the Retinal Pigment Epithelium" Zola M, Ambresin A, Zografos L. **Image Gallery**, 4th International Congress on OCT Angiography and Advances in Angio- OCT, Rome 16th-17th December 2016.

"The Genetic of CSCR" Zola M, Behar-Cohen F. **Oral presentation invited speaker**, 13th ISOPT Clinical meeting, Rome 1st and 2nd December 2016.

"Clinical Use of Intraocular Steroids" Zola M, Mantel I. **Oral presentation invited speaker**, 13th ISOPT Clinical meeting, Rome 1st and 2nd December 2016.

"Evolution of Short-wavelength Autofluorescence changes in Central Serous Chorioretinopathy over 12 months." Zola M, Sanghi P, Patrao N, Menon D, Hykin P, Sivaprasad S. **Poster Presentation**, ARVO Meeting, April 30th - May 5th 2016 Seattle.

"Use of a long-acting dexamethasone intravitreal implant in non infectious uveitis complicated with macular oedema: preliminary results of repeated injections" Zola M, Lorenzi U, Machetta F, Fea AM, Briamonte C, Grignolo FM. **Oral Presentation**, 39th Meeting of the North Western Italian Society of Ophthalmology, 3rd- 4th Oct 2014, Sanremo.

"Anterior chamber dislocation of the 0.7mg dexamethasone intravitreal implant" Zola M, Briamonte C, Aragno V, Fea AM, Lorenzi U, Machetta F, Grignolo FM. **Poster Presentation**, 93rd National Congress, Italian Society of Ophthalmology, 29th Nov – 3rd Dec 2013, Rome.

Co-Autore

"Adjuvant ursodeoxycholic acid for retinal detachment: a potential neuroprotective therapy."

A Daruich, E Picard, M Zola, H Henry, Jeffrey H Boatright; Francine F Behar-Cohen, **Oral Presentation**, ARVO Meeting, 28th April, 2nd May 2019, Vancouver.

"Comparison of multicolour imaging technique with en-face OCT in the visualisation of idiopathic epiretinal membrane." J-A Pournaras, M. Zola, I. Papisavvas, L. Marchionno, A. Ambresin. **Oral Presentation**, Euretina Meeting, 20th-23rd September 2018, Vienna.

"Influence of structural SDOCT characteristics in the detection of choroidal neovascularization due to AMD using OCT angiography" I. Papisavvas, Dirani A, Pournaras J-A, Zola M, Sherif M, Ambresin A. **Oral Presentation**, Euretina Meeting, 20th-23rd September 2018, Vienna.

"Optical Coherence Tomography Angiography ability to diagnose Choroidal Neovascularization in Central Serous Chorioretinopathy patients vs. classic angiography" WOC 2018

"Risk factors for recurrences of Central Serous Chorioretinopathy" A. Matet, A. Daruich, M. Zola, F. Behar-Cohen.

Oral Presentation, ARVO Meeting, May 2017 Baltimore.

"*Central serous chorioretinopathy in women*" P. Sanghi, M. Zola, N. Patrao, J. Ramu, S. Sivaprasad, P. Hykin. **Poster Presentation**, ARVO Meeting, May 2016 Seattle.

"*Significance of Choroidal Hyper-reflective foci visualised on Enhanced Depth Imaging in Central Serous Chorioretinopathy*" N. Patrao, P. Sanghi, M. Zola, L. Nicholson, S. Sivaprasad, P. Hykin.

Poster Presentation, ARVO Meeting, May 2016 Seattle.

"*Acute Necrotising Retinitis: Our Experience*" Pignata G, Lavia C, Zola M, Machetta F, Fea, Grignolo F, **Poster Presentation**, 96th National Congress, Italian Society of Ophthalmology, Nov 2015.

"*Ocular Sarcoidosis*" Lavia C, Pignata G, Zola M, Machetta F, Fea, Grignolo F, **Poster Presentation**, 96th National Congress, Italian Society of Ophthalmology, Nov 2015

"*Management of non infectious uveitis with an intravitreal steroid implant.*" **Poster Presentation**, 93rd National Congress, Italian Society of Ophthalmology, 29th Nov –3rd Dec 2013, Rome.

Fatto a Parigi, il 24 Ottobre 2023